Eli Lilly News

In this article

Reuters. The drugmaker has accused the four compounding pharmacies, which make customized drug preparations for customers, of violating federal and state consumer protection and competition laws by selling unregulated versions of Mounjaro.

Supply problems and insurance complications have made it difficult for many patients to start and stay on new prescription medications used to treat obesity

alcohol industry has been thriving despite a streak of threats: the legalization of marijuana, a trade war with China that hampers US exports, the rise of the sober-curious movement. Now a new risk is here: weight loss drugs. Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy have gained popularity as a fast way to lose weight, thanks to celebrities such as Khloe Kardashian and Elon Musk.

Each month Tina Marie Porter pays about $1,000 out of pocket for Mounjaro. To make up for the extra monthly expense, the 49-year-old director of operations takes on more assignments and seeks odd jobs. Porter belongs to a growing population of people taking extra measures to cover the full or almost-full price of popular drugs used for weight loss, after their insurance denied them coverage.

Shareholders in U.S. firms saw dividends grow by 4.6% on an underlying basis in the second quarter of 2023 and by 2.9% on a headline basis including special dividends, exchange rate effects and other technical factors.

Half of the world’s dividends in Q2 were contributed by banks.

By Brendan Pierson

Here is your Pro Recap of the biggest earnings reports you may have missed this week and how analysts responded: numbers out of Disney, Eli Lilly, UPS, and Alibaba.

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Eli Lilly, DraftKings, United States Cellular, and Dish Network.

Medicare coverage. That will have significant implications for our society, where four in 10 adults are obese, as well as for investors in this space’s emerging duopoly: Eli Lilly and Novo. We always knew Wegovy, the weekly anti-obesity injections, helps patients lose weight.

Investing.com — U.S. stocks were falling on Tuesday, handing back some of the previous session’s strong gains as investors awaited the release of a fresh batch of corporate earnings.

Investing.com — U.S. stock futures point lower ahead of a raft of new corporate earnings that include results from Eli Lilly and UPS. Elsewhere, SoftBank slips to a surprise quarterly loss, although its flagship Vision Fund is boosted by a rebound in tech valuations, while Tesla shares fall after the electric car maker unexpectedly announces the departure of its finance chief.

Investing.com — U.S. futures retreated Tuesday, with corporate results to the fore as the quarterly earnings season draws to a close.

In this article

Wall Street's main indices ended lower on Friday, capping off a losing week as investors digested the latest U.S. jobs report and disappointing earnings from Apple (NASDAQ:AAPL).

inflation data for July and few major earnings. The Consumer Price Index (CPI) report for July is slated to be released on 10 August and the Producer Price Index (PPI) report on 11 August. Next week, earnings reports of following companies are due – Tyson Foods, Lucid Group, Skyworks Solutions, Paramount Global, Palantir Technologies, Eli Lilly, United Parcel Service, Coupang, Li Auto, Datadog, Disney, Trade Desk, Roblox, Wynn Resorts, Brookfield Asset Management, Alibaba, US Foods, Ralph Lauren, Spectrum Brands and Soho House.

By Deena Beasley

Alzheimer's disease experts are revamping the way doctors diagnose patients with the progressive brain disorder — the most common type of dementia — by devising a seven-point rating scale based on cognitive and biological changes in the patient. The proposed guidelines, unveiled by experts on Sunday in a report issued at an Alzheimer's Association conference in Amsterdam, embrace a numerical staging system assessing disease progression similar to the one used in cancer diagnoses. They also eliminate the use of terms like mild, moderate and severe. The revamp — replacing guidelines issued in 2018 — was prompted by the increased availability of tests detecting key Alzheimer's-related proteins such as beta amyloid in the blood and new treatments that require confirmation of disease pathology prior to use. The new system is designed to be more accurate and better reflect a person's underlying disease, according to Dr. Clifford Jack of the Mayo Clinic in Rochester, Minnesota, lead author of the report sponsored by the Alzheimer's Association and the National Institute of Aging, a part of the U.S. government's National Institutes of Health. The change comes at a time when doctors are preparing to identify and treat patients with Eisai and Biogen's drug Leqembi, which won Food and Drug Administration approval this month, and Eli Lilly's experimental drug donanemab, which is now under FDA review.

By Julie Steenhuysen